PPD: A Common Complication That Is Too Often Undertreated

Postpartum depression (PPD) is among the most common medical complications of the peripartum period, with epidemiologic estimates placing global prevalence as high as 20%.¹ It is defined as a major depressive episode with peripartum onset—beginning during pregnancy or in the weeks following delivery—and it is distinct from the transient “baby blues” in both severity and duration.

What makes PPD clinically urgent is not only how frequently it occurs but how long it can persist. A substantial share of diagnosed patients continue to experience symptoms well into the year or years following delivery. During that window, the consequences extend well beyond the mother. Untreated maternal depression is associated with impaired mother–infant bonding, disruptions to early parenting and feeding practices, and measurable effects on a child’s long-term cognitive and emotional development—a burden shared across the entire family that compounds when treatment is delayed or inadequate.²

Screening tools such as the Edinburgh Postnatal Depression Scale (EPDS) have made case-finding more feasible in obstetric and primary care settings,³ yet identification does not guarantee timely treatment. Many patients hesitate to start pharmacotherapy because of concerns about breastfeeding, stigma, or the practical demands of caring for a newborn. Clinicians, in turn, may weigh the slow onset of conventional antidepressants against the real-time deterioration of a patient’s functioning.

The result is a treatment gap: a highly prevalent, consequential, and treatable disorder that frequently goes unmanaged during the precise period when intervention matters most. Addressing PPD effectively requires not just recognition but treatment options that align with the realities of new motherhood—rapid relief, manageable side effects, and compatibility with infant care.